Rasburicase in Tumor Lysis Syndrome

Program of Rasburicase in the Treatment of Hyperuricemia in Children and Adolescent Patients With or at Risk of Tumor Lysis Syndrome.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00302653

Enrollment

Registered

2006-03-14

Start date

2006-02-28

Completion date

Unknown

Last updated

2009-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperuricemia

Brief summary

The purpose of this study is to determine whether rasburicase is effective and safety in correcting hyperuricemia.

Interventions

DRUGRasburicase

Rasburicase 0,20mg/Kg/Day once a day 3-7 days

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

No minimum to 18 Years

Healthy volunteers

Inclusion criteria

List of inclusion Criteria: * Acute hyperuricemia patients(uric acid\>8.0 mg/dl) before/during chemotherapy for hematologic malignancies. List of

Exclusion criteria

* Hypersensitivity to uricases or any of the excipients. * Known history of hemolytic anemia (G6PD deficiency). The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Design outcomes

Primary

Measure	Time frame
Percentage of patients with uric acid greater-than-normal laboratory levels (hyperuricemia)	24-48 hours after last dose of rasburicase
Adverse events occurrence	During the study

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026